Cargando…

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers

BACKGROUND: Triple negative breast cancers (TNBC) are a more aggressive subset of breast cancer. A better understanding of its biology could allow the rational development of targeted therapies. METHODS: We extensively analyzed the EGFR/PI3K/PTEN axis in a large, homogeneous population of TNBC to he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacot, William, Mollevi, Caroline, Fina, Frédéric, Lopez-Crapez, Evelyne, Martin, Pierre-Marie, Colombo, Pierre-Emmanuel, Bibeau, Frédéric, Romieu, Gilles, Lamy, Pierre-Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683760/ https://www.ncbi.nlm.nih.gov/pubmed/26680641 http://dx.doi.org/10.1186/s12885-015-1977-3

Ejemplares similares

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
por: Jacot, William, et al.
Publicado: (2011)

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
por: Jacot, William, et al.
Publicado: (2013)

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
por: Darlix, Amélie, et al.
Publicado: (2016)

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
por: Guiu, Séverine, et al.
Publicado: (2018)

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers
por: Lamy, Pierre-Jean, et al.
Publicado: (2011)

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
por: Jacot, William, et al.
Publicado: (2020)

Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers
por: Chabab, Ghita, et al.
Publicado: (2020)

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
por: Assenat, Eric, et al.
Publicado: (2015)

Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer
por: Bobrie, Angélique, et al.
Publicado: (2022)

Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine
por: Lamy, Pierre-Jean, et al.
Publicado: (2012)

Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2009)

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2019)

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
por: Velazquez, Carolina, et al.
Publicado: (2023)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

Specific Extracellular Matrix Remodeling Signature of Colon Hepatic Metastases
por: Del Rio, Maguy, et al.
Publicado: (2013)

Mutational pattern of PIK3CA exon 20 in circulating DNA in breast cancer
por: Ibrahim, Iman Hassan, et al.
Publicado: (2022)

PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients
por: Mangone, Flavia R., et al.
Publicado: (2012)

The quest for the optimal biomarker: is extending the spectrum of targeted PIK3CA mutations in breast cancer carcinoma worthwhile?
por: Quesada, Stanislas, et al.
Publicado: (2023)

Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse
por: du Manoir, Stanislas, et al.
Publicado: (2013)

PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer
por: Manceau, Gilles, et al.
Publicado: (2015)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
por: Cossu-Rocca, Paolo, et al.
Publicado: (2015)

KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues
por: Solassol, Jérome, et al.
Publicado: (2011)

KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
por: Lopez-Crapez, E, et al.
Publicado: (2010)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the “APAD1” randomized controlled trial
por: Carayol, Marion, et al.
Publicado: (2019)

Muscle hemihypertrophy syndrome with PIK3CA gene mutation associated with Tourette syndrome
por: Hayoun-Vigouroux, Mathilde, et al.
Publicado: (2022)

Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations
por: Dugay, Frédéric, et al.
Publicado: (2017)

CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type
por: Barbi, Stefano, et al.
Publicado: (2010)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma
por: Saida, Kosuke, et al.
Publicado: (2018)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
por: Lu, Hong-Yang, et al.
Publicado: (2018)

Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome
por: Scholl, Suzy, et al.
Publicado: (2019)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

The sensitivity and efficacy method of PIK3CA exon 9 E545A as a high diagnostic accuracy in breast cancer
por: Desriani, et al.
Publicado: (2018)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Corrigendum to ‘clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome’
por: Scholl, Suzy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ej2743109nd943d5u1ik5uj9rm